Mirum Pharmaceuticals, Inc. Additional Paid in Capital, Common Stock
Mirum Pharmaceuticals, Inc. (MIRM) had Additional Paid in Capital, Common Stock of $1.52 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $1.52B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.70B.
- 2025-12-31: Additional Paid in Capital, Common Stock $981.88M.
- 2025-09-30: Additional Paid in Capital, Common Stock $953.82M.
| Period end | Additional Paid in Capital, Common Stock |
|---|---|
| 2026-06-30 | $1.52B 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.70B 10-Q · filed 2026-05-06 |
| 2025-12-31 | $981.88M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $953.82M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $919.52M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $892.37M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $870.19M 10-K · filed 2026-02-25 |
| 2024-09-30 | $851.49M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $835.62M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $816.13M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $803.26M 10-K · filed 2025-02-26 |
| 2023-09-30 | $791.11M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $575.52M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $563.96M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $535.07M 10-K · filed 2024-03-15 |
| 2022-09-30 | $526.10M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $431.57M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $402.82M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $377.40M 10-K · filed 2023-03-08 |
| 2021-09-30 | $371.10M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $363.34M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $357.58M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $345.18M 10-K · filed 2022-03-09 |
| 2020-09-30 | $256.05M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $250.35M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $247.35M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $200.12M 10-K · filed 2021-03-09 |
| 2019-09-30 | $198.05M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $1.89M 10-Q · filed 2019-08-28 |
| 2018-12-31 | $34.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |